Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes. Part II

Cell cycle progression is dependent on the intracellular iron level and chelators can lead to iron depletion and decrease cell proliferation. This antiproliferative effect can be inhibited by exogenous iron. In this work, we present the synthesis of some new synthetic calix[4]arene podands bearing diamino-tetraesters, diamino-tetraalcohols, diamino-tetraacid and tetraaryloxypentoxy groups at the lower rim, designed as potential iron chelators. We report their effect on cell proliferation, in comparison with the new oral chelator ICL670A (4-[3,5-bis-(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid). The antiproliferative effect of these new compounds was studied in the human hepatocarcinoma HepaRG cell cultures using cell nuclei counting after staining with the DNA intercalating fluorescence dye, Hoechst 33342. Their cytotoxicity was evaluated by the extracellular LDH activity. Preliminary results indicated that their antiproliferative effect was mainly due to their cytotoxicity. The efficiency of these compounds, being comparable to that of ICL670, was independent of iron depletion. This effect remains to be further explored. Moreover, it also shows that the new substituted calix[4]arenes could open the way to valuable new approaches for medicinal chemistry scaffolding.

[1]  Xiaole Kong,et al.  Design of iron chelators with therapeutic application. , 2012, Dalton transactions.

[2]  G. Lescoat,et al.  Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes , 2010, Journal of enzyme inhibition and medicinal chemistry.

[3]  S. Subramanian,et al.  On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia. , 2008, Bioorganic & medicinal chemistry letters.

[4]  L. Mutihac.  Functionalized calix[n]arenes as membrane transporters for biological compounds. A minireview. , 2008, Current drug discovery technologies.

[5]  W. Wilson,et al.  Synthesis and antiprotozoal activity of novel bis-benzamidino imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines. , 2008, Bioorganic & medicinal chemistry.

[6]  P. Jose,et al.  Lower-Rim Substituted Calixarenes and Their Applications , 2007, Bioinorganic chemistry and applications.

[7]  R. Bergeron,et al.  The design, synthesis, and evaluation of organ-specific iron chelators. , 2006, Journal of medicinal chemistry.

[8]  D. Richardson,et al.  Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. , 2006, Journal of medicinal chemistry.

[9]  C. Raston,et al.  Supersized bilayers based on an O-alkyl substituted calix[4]arene , 2006 .

[10]  W. Wilson,et al.  Synthesis, DNA affinity, and antiprotozoal activity of linear dications: Terphenyl diamidines and analogues. , 2006, Journal of medicinal chemistry.

[11]  K. Rauch,et al.  Access to Variously Substituted 5,6,7,8‐Tetrahydro‐3H‐quinazolin‐4‐ones via Diels–Alder Adducts of Phenyl Vinyl Sulfone to Cyclobutene‐Annelated Pyrimidinones , 2006 .

[12]  S. Perrotta,et al.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. , 2006, Blood.

[13]  G. Lescoat,et al.  Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes , 2006, Journal of enzyme inhibition and medicinal chemistry.

[14]  Nolwenn Le Meur,et al.  Hepatocyte iron loading capacity is associated with differentiation and repression of motility in the HepaRG cell line. , 2006, Genomics.

[15]  D. Richardson,et al.  The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer , 2005, Pharmacological Reviews.

[16]  K. Fischer,et al.  Self-assembly of programmed building blocks into structurally uniform dendrimers. , 2005, Journal of the American Chemical Society.

[17]  E. De Clercq,et al.  Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. , 2005, Journal of medicinal chemistry.

[18]  J. Leger,et al.  First Synthesis of 1,3-Alternate 25,27-Dialkyloxy-5,17-diarylcalix[4]arenes-crown-6 as New Cesium Selective Extractants by Suzuki Cross-coupling Reaction , 2004 .

[19]  D. Richardson,et al.  Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity , 2003, American journal of hematology.

[20]  B. Hasinoff.  The intracellular iron sensor calcein is catalytically oxidatively degraded by iron(II) in a hydrogen peroxide-dependent reaction. , 2003, Journal of inorganic biochemistry.

[21]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Richardson,et al.  The role of iron in cell cycle progression and the proliferation of neoplastic cells. , 2002, Biochimica et biophysica acta.

[23]  D. Richardson,et al.  Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. , 2002, Blood.

[24]  J. Leger,et al.  Synthesis and Cesium Binding Affinity of New 25,27-Bis(alkyloxy)calix[4]arene-crown-6 Conformers in Relation to the Alkyl Pendent Moiety , 2002 .

[25]  J. Porter,et al.  Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. , 2002, Best practice & research. Clinical haematology.

[26]  D. Richardson.  Iron chelators as therapeutic agents for the treatment of cancer. , 2002, Critical reviews in oncology/hematology.

[27]  R. Hider,et al.  Design of clinically useful iron(III)‐selective chelators , 2002, Medicinal research reviews.

[28]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. , 1995, Blood.

[29]  M. Rouan,et al.  Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[30]  J. Leger,et al.  Synthesis of Cone, Partial-Cone, and 1,3-Alternate 25,27-Bis[1-(2-ethyl)hexyl]- and 25,27-Bis[1-(2-tert-butoxy)ethyl]calix[4]arene-crown-6 Conformers as Potential Selective Cesium Extractants. , 2001 .

[31]  F. Sansone,et al.  Calixarenes in Bioogranic and Biomimetic Chemistry , 2001 .

[32]  Guillon,et al.  Synthesis of cone, partial-cone, and 1,3-alternate 25, 27-Bis , 2000, The Journal of organic chemistry.

[33]  G. Lescoat,et al.  Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. , 2000, Carcinogenesis.

[34]  A. Sartorelli,et al.  Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. , 2000, Biochemical pharmacology.

[35]  N. Andrews,et al.  Disorders of iron metabolism. , 1999, The New England journal of medicine.

[36]  M. Fontecave,et al.  Calcein as a Fluorescent Probe for Ferric Iron , 1999, The Journal of Biological Chemistry.

[37]  S. E. Matthews,et al.  Calix[4]arenes with CMPO functions at the narrow rim. Synthesis and extraction properties , 1999 .

[38]  G. Lescoat,et al.  Deferoxamine arrests in vitro the proliferation of porcine hepatocyte in G1 phase of the cell cycle. , 2008, Liver.

[39]  D. Naidoo,et al.  Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. , 1998, Cancer research.

[40]  D. Richardson.  Potential of iron chelators as effective antiproliferative agents. , 1997, Canadian journal of physiology and pharmacology.

[41]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. , 1997, Blood.

[42]  A. Shanzer,et al.  Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. , 1996, Blood.

[43]  U. Ramenghi,et al.  Effect of different exposures to desferrioxamine on neuroblastoma cell lines. , 1995, Pediatric hematology and oncology.

[44]  J. Olsen,et al.  Cancer risk following primary hemochromatosis: A population‐based cohort study in Denmark , 1995, International journal of cancer.

[45]  G. Koren,et al.  Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. , 1994, Blood.

[46]  P. Brissot,et al.  Preneoplastic significance of hepatic iron–free foci in genetic hemochromatosis: A study of 185 patients , 1993, Hepatology.

[47]  J Lucas,et al.  Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. , 1993, Cancer research.

[48]  A. Hoffbrand,et al.  Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. , 1992, Blood.

[49]  G. Koren,et al.  Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. , 1992, Blood.

[50]  A. Casnati,et al.  A general synthesis of calix[4]arene monoalkyl ethers , 1991 .

[51]  K. Nouri-Aria,et al.  Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. , 1990, Immunology.

[52]  M. Stahlhut,et al.  Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. , 1988, Cancer research.

[53]  C. Gutsche,et al.  Calixarenes. Part 12. The Synthesis of Functionalized Calixarenes. , 1986 .

[54]  E. Romano,et al.  The effect of desferrioxamine on the proliferative response of rat lymphocytes stimulated with various mitogens in vitro. , 1984, Immunopharmacology.

[55]  D Rodbard,et al.  Automated computer analysis for enzyme-multiplied immunological techniques. , 1977, Clinical chemistry.

[56]  S. S. Berg,et al.  138. The search for chemotherapeutic amidines. Part X. Substituted 4 : 4′-diamidino-αω-diphenoxyalkanes and -diphenyl ethers , 1949 .

[57]  E. G. Wakefield,et al.  ABSORPTION AND EXCRETION OF IRON , 1945 .